Since Forward Science's FDA Clearance of SalivaMAX on December 23, 2015, the company has consistently demonstrated the product's effectiveness through multiple clinical studies. Forward Science has partnered with oncology centers showing the benefit of SalivaMAX for cancer patients, along with public health centers to showcase its impact on overall oral health. New data from a study conducted at The University of Colorado’s School of Dental Medicine shows SalivaMAX’s benefits extend beyond soft tissue. See Clifton M. Carey. Remineralization of Early Enamel Lesions with Apatite-Forming Salt. Dent. J. 2023, 11(8), 182; https://doi.org/10.3390/dj11080182
"SalivaMAX has been one of those products that has proven to have many different uses for patient's oral healthcare" shares Forward Science's Chief Scientific Officer Dr. Brian Pikkula. "Our continued support for additional research shows our ongoing commitment to science-based outcomes for our products." Forward Science continues to partner with clinicians to prove the efficacy of its product line. In addition to its current products, Forward Science’s R&D team is actively innovating current technologies to create more cost-effective solutions for better patient outcomes.
To read this study and other research regarding SalivaMAX, please visit https://forwardscience.com/research#salivamax-research
Contact Forward Science here to learn more about partnering with the company.
